KR20100055498A - 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물 - Google Patents

약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물 Download PDF

Info

Publication number
KR20100055498A
KR20100055498A KR1020107006136A KR20107006136A KR20100055498A KR 20100055498 A KR20100055498 A KR 20100055498A KR 1020107006136 A KR1020107006136 A KR 1020107006136A KR 20107006136 A KR20107006136 A KR 20107006136A KR 20100055498 A KR20100055498 A KR 20100055498A
Authority
KR
South Korea
Prior art keywords
drug
polymer
target
polymer unit
micelle
Prior art date
Application number
KR1020107006136A
Other languages
English (en)
Korean (ko)
Inventor
야스키 가토
미츠노리 하라다
히로유키 사이토
타츠유키 하야시
Original Assignee
나노캬리아 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나노캬리아 가부시키가이샤 filed Critical 나노캬리아 가부시키가이샤
Publication of KR20100055498A publication Critical patent/KR20100055498A/ko

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644Transferrin, e.g. a lactoferrin or ovotransferrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107006136A 2008-07-29 2009-07-29 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물 KR20100055498A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008194825 2008-07-29
JPJP-P-2008-194825 2008-07-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117014312A Division KR101468268B1 (ko) 2008-07-29 2009-07-29 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물

Publications (1)

Publication Number Publication Date
KR20100055498A true KR20100055498A (ko) 2010-05-26

Family

ID=41610525

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107006136A KR20100055498A (ko) 2008-07-29 2009-07-29 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물
KR1020117014312A KR101468268B1 (ko) 2008-07-29 2009-07-29 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117014312A KR101468268B1 (ko) 2008-07-29 2009-07-29 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물

Country Status (13)

Country Link
US (1) US8741339B2 (ja)
EP (1) EP2281576B1 (ja)
JP (1) JP4538666B2 (ja)
KR (2) KR20100055498A (ja)
CN (1) CN101808668B (ja)
AU (1) AU2009277456B2 (ja)
CA (1) CA2695611C (ja)
DK (1) DK2281576T3 (ja)
ES (1) ES2432152T3 (ja)
HK (1) HK1148216A1 (ja)
PL (1) PL2281576T3 (ja)
PT (1) PT2281576E (ja)
WO (1) WO2010013836A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
EP2424359A4 (en) 2009-04-30 2014-01-15 Intezyne Technologies Inc POLYMIC MICELLES WITH ANTHRACYCLINES FOR THE TREATMENT OF CANCER
TWI533885B (zh) * 2011-03-31 2016-05-21 Nanocarrier Co Ltd And a pharmaceutical composition comprising a block copolymer containing a boronic acid compound
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
MX2014005540A (es) 2011-11-17 2014-09-22 Univ Tokyo Copolimero en bloque que tiene un grupo acido fenilboronico introducido dentro de el y uso del mismo.
JP6195171B2 (ja) 2012-04-27 2017-09-13 国立大学法人 東京大学 核酸デリバリー用ユニット構造型医薬組成物
JP5692887B1 (ja) * 2013-05-17 2015-04-01 ナノキャリア株式会社 ポリマーミセル医薬組成物
WO2015170757A1 (ja) 2014-05-08 2015-11-12 国立大学法人 東京大学 医薬組成物
WO2016161102A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York A supramolecular chitosan complex drug delivery platform
US20190330317A1 (en) 2016-06-15 2019-10-31 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2017218825A1 (en) 2016-06-15 2017-12-21 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2018025699A1 (ja) * 2016-08-02 2018-02-08 日本化薬株式会社 アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
JP6644326B2 (ja) 2017-08-31 2020-02-12 国立大学法人 東京大学 核酸搭載ユニット型ポリイオンコンプレックス
CN115003285B (zh) * 2020-01-15 2024-05-14 超新星生物有限公司 用于减少局部脂肪的气体发泡型胶束
EP4408457A1 (en) 2021-09-30 2024-08-07 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
JP2023138437A (ja) * 2022-03-17 2023-10-02 日油株式会社 ポリエチレングリコール誘導体の製造方法
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US7371781B2 (en) * 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
NZ562064A (en) * 2005-04-01 2011-03-31 Intezyne Technologies Inc Polymeric micelles for drug delivery
EP1878766B1 (en) * 2005-05-02 2020-01-01 The University of Tokyo Electrostatic bonding type polymer vesicle
WO2007048121A2 (en) * 2005-10-20 2007-04-26 Centocor, Inc. Methods of preparing targeted immunoliposomes
JP5028564B2 (ja) * 2005-10-31 2012-09-19 宮崎県 肝疾患治療用又は予防用の血中滞留型多相エマルション製剤及びその製造方法
JP5046957B2 (ja) 2005-12-05 2012-10-10 ナノキャリア株式会社 フッ素系有機溶媒を用いた薬物封入ポリマーミセルを含有する医薬組成物の製造方法
EP2011516A4 (en) * 2006-04-24 2010-06-23 Nanocarrier Co Ltd PROCESS FOR THE PRODUCTION OF A POLYMERIC MICELLE THAT CONTAINS A CHEMICAL PRODUCT OF LOW MOLECULAR WEIGHT ENCAPSULATED IN IT
KR101444274B1 (ko) * 2006-10-19 2014-09-26 나노캬리아 가부시키가이샤 약제복합체용 블록 공중합체 및 의약조성물
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery

Also Published As

Publication number Publication date
KR20110075054A (ko) 2011-07-05
US20100221320A1 (en) 2010-09-02
HK1148216A1 (en) 2011-09-02
CN101808668B (zh) 2012-06-27
CA2695611C (en) 2011-02-01
AU2009277456A1 (en) 2010-02-04
EP2281576B1 (en) 2013-07-24
EP2281576A4 (en) 2011-07-20
US8741339B2 (en) 2014-06-03
AU2009277456B2 (en) 2011-05-26
WO2010013836A1 (ja) 2010-02-04
PT2281576E (pt) 2013-10-01
ES2432152T3 (es) 2013-12-02
PL2281576T3 (pl) 2013-12-31
KR101468268B1 (ko) 2014-12-02
CA2695611A1 (en) 2010-01-29
EP2281576A1 (en) 2011-02-09
DK2281576T3 (da) 2013-10-28
JP4538666B2 (ja) 2010-09-08
CN101808668A (zh) 2010-08-18
JPWO2010013836A1 (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
KR101468268B1 (ko) 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물
KR102051038B1 (ko) 나노입자 약물 컨쥬게이트
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
Chae et al. Improved antitumor activity and tumor targeting of NH2-terminal–specific PEGylated tumor necrosis factor–related apoptosis-inducing ligand
CN110078915B (zh) 用硝基苯硼酸组合物稳定的纳米粒子
CN102145176A (zh) 一种靶向蛋白-聚乙二醇-抗癌药物连接物
JP6876618B2 (ja) 治療目的のための抗体−ウレアーゼコンジュゲート
CN102123698A (zh) 载体纳米颗粒和相关的组合物、方法和系统
TW200416035A (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP5692887B1 (ja) ポリマーミセル医薬組成物
ES2856055T3 (es) Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
KR102279429B1 (ko) 멀티 암 표적 항암 콘쥬게이트
Tang et al. Peptide-functionalized delivery vehicles for enhanced cancer therapy
US11975077B2 (en) Guanylurea functionalized peptides and proteins for therapeutics
Canato et al. Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
CN108452319A (zh) 靶向cd20的抗体偶联药物制剂
US20060286657A1 (en) Novel bioconjugation reactions for acylating polyethylene glycol reagents
CN102652836A (zh) 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
WO2003017938A2 (en) Conjugates targeted to target receptors
CN113842467A (zh) 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用
KR101562369B1 (ko) 폴리히스티딘과 인지질의 결합체를 함유한 pH 감응형 지질펩타이드 및 그의 제조방법
Park et al. Functionalizing Liposomes with Dual Aptamers for Targeting of Breast Cancer Cells and Cancer Stem Cells
CN116199747A (zh) 一种力达霉素前药、制备方法及其在制备抗肿瘤药物中的应用
WO2015157213A1 (en) Egfr-targeted nanoparticles
KR20240099391A (ko) 폴리에틸렌이민 및 폴리에틸렌 글리콜을 포함하는 표적화된 선형의 컨쥬게이트 및 이를 포함하는 다중복합체

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
A107 Divisional application of patent